New biotech company to commercialize novel UD gene-repair ...( y African Americans. Those afflicted wi...),Health

y African Americans. Those afflicted with the disease produce sickle- or crescent-shaped blood cells instead of smooth, round blood cells. These sickle cells tend to get stuck in the blood vessels, blocking the flow of blood to the limbs and organs, often causing pain, organ damage and anemia in the process.

Spinal muscular atrophy is a genetic disease caused by the progressive degeneration of motor neurons in the spinal cord, resulting in weakness and wasting of the voluntary muscles. Weakness is often more severe in the legs than in the arms. The disease affects approximately one in 6,000 babies, and about one in 40 people are genetic carriers, according to Families of Spinal Muscular Atrophy.

Herr said the company's immediate strategy is to advance the new technologies to clinical trials, assemble a leadership team around its UD founders, and identify strategic partners.

'"/>

Contact: Tracey Bryant
tbryant@udel.edu
302-831-8185
University of Delaware
24-Apr-2007


Page: 1 2
Related medicine news :

1. Warning to government from biotech on PBS changes
2. NIH awards funding to biotech firm for heart disease
3. Italian doctors get their information on medicines from drug company sales reps
4. Drug company sales visits influenced doctors, study finds
5. The Clorox companys new personal care product lends a hand
6. Drug company reports should be read with caution, warn doctors
7. Spinoff company based on technology developed at OHSU enters new business phase
8. Research reveals tobacco companys role in Chinas cigarette smuggling crisis
9. Patients groups should declare pharmaceutical company funding
10. Indiana seed fund invests in breast cancer detection startup company
11. University of Utah surgeon returns from Iraq to help start-up company fight cancer